STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pathos raised $237 million in a Series E fundraising round, led by Bristol Myers Squibb, bringing the company's valuation to approximately $3 billion.
- Pathos is expanding its focus from oncology to neurological conditions, with a new partnership with Bristol Myers Squibb that will first target Alzheimer's treatments.
- Pathos is utilizing new datasets from Tempus AI as part of its expansion into new therapeutic areas.
- Pathos's proprietary AI model, Foundry, uses thousands of agents to analyze clinical data, genomics, and competition to calculate the probability of success for its clinical assets.
- Pathos uses its AI model to guide decisions on which drug candidates to pursue, which patient populations to test them in, and how to design clinical trials.
Why it matters: The funding and partnership with a major pharmaceutical company validates the role of AI in de-risking drug development, a field with a high failure rate. For Bristol Myers Squibb, this represents a strategic investment in a pipeline that could yield new treatments for costly, complex neurological diseases like Alzheimer's.
Ask SkimNews
